Associate Professor Marina Pajic
Associate Professor Marina Pajic completed her PhD in the laboratory of Professor Michelle Haber at the Children’s Cancer Institute (CCI), University of New South Wales, where she investigated chemoresistance mechanisms in childhood cancers, supported by a University Postgraduate Award and a CCI Postgraduate Scholarship. In 2006, Marina moved to work with Professor Piet Borst at the Netherlands Cancer Institute where she developed physiologically-relevant mouse models to study chemotherapy resistance and discovered new mechanisms which guide survival of therapy-resistant cancer-initiating cells during a process termed “transient dormancy”. Following her return to Australia in 2010 and collaborative efforts within the International Cancer Genome Consortium, Marina has established unique personalised medicine projects for pancreatic cancer, supported by three fellowships from Cancer Institute NSW. Since 2013 Marina has led the Personalised Cancer Therapeutics Lab at the Garvan Institute of Medical Research. Understanding the role of “-omic” alterations in cancer progression and treatment failure with a view to developing novel effective therapeutic approaches are the focus of her research. She takes an active role in training emerging scientists (Honours and PhD projects). Marina engages and communicates regularly with the public through Garvan’s public events. She is an EACR ambassador and co-director of the Australasian Pancreatic Club.
- 2001University postgraduate bursary award (University of Auckland)
- 2002Postgraduate Scholarship in Cellular Cancer Pharmacology (University of Sydney)
- 2003University Postgraduate Award (University of Sydney) and Children’s Cancer Institute of Australia Postgraduate Scholarship (University of New South Wales)
- 2011CINSW Early Career Development Fellowship
- 2011Phillip Hemstritch fellowship in pancreatic cancer
- 2012Conference Awards (EACR Cancer Genomics Conference - Cambridge - UK; Australian Division of International Academy of Pathology - 38th annual scientific meeting - Australia; EACR 22nd Biennial Congress - Barcelona - Spain)
- 2012European Association for Cancer Research (EACR) ambassador
- 2013Travel Grants (CASS Foundation - Sydney Catalyst)
- 2014Australasian Pancreatic Club (APC) Co-director; Co-organiser of annual scientific conferences
- 2014CINSW Career Development Fellowship
- 2017Cancer Institute New South Wales (CINSW) Career Development Fellowship
- 2017NSW Premier's Award for Outstanding Cancer Research Fellow
- 2018Lorne Genome Young Investigator Award
- 2019NHMRC RD Wright Biomedical Career Development Fellowship Level 2
- 2020Australian Academy of Science Ruth Stephens Gani Medal
- 2023Nature cancer10.1038/s43018-023-00614-y
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
- 2022Advanced genetics (Hoboken, N.J.)10.1002/ggn2.202200014
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem.
CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
- 2021Frontiers in oncology10.3389/fonc.2021.750852
Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of Amplification: Implications for Novel Personalized Therapy.
- 2021Science advances10.1126/sciadv.abh0363
Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status.